Effects of Recombinant Human Erythropoietin on Resistance Artery Endothelial Function in Stage 4 Chronic Kidney Disease
Role of Oxidative Stress and Endothelin-1

Marie Briet, MD, PhD; Tlili Barhoumi, PhD; Muhammad Oneeb Rehman Mian, MSc; Cristina Sierra, MD; Pierre Boutouyrie, MD, PhD; Michael Davidman, MD; David Bercovitch, MD; Sharon J. Nessim, MD; Gershon Frisch, MD; Pierre Paradis, PhD; Mark L. Lipman, MD; Ernesto L. Schiffrin, MD, PhD

Background—Recent studies have raised concern about the safety of erythropoiesis-stimulating agents because of evidence of increased risk of hypertension and cardiovascular morbidity and mortality in chronic kidney disease (CKD) patients. In the present study, we investigated the effects of recombinant human erythropoietin (EPO) on endothelial function of gluteal subcutaneous resistance arteries isolated from 17 stage 4 patients (estimated glomerular filtration rate 21.9±7.4 mL/min per 1.73 m²) aged 63±13 years.

Methods and Results—Arteries were mounted on a pressurized myograph. EPO impaired endothelium-dependent relaxation in a concentration-dependent manner. The maximal response to acetylcholine with EPO at 1, 10, and 20 IU/mL was reduced by 12%, 34%, and 43%, respectively, compared with the absence of EPO (P<0.001). EPO-induced endothelial dysfunction was significantly associated with carotid stiffness and history of cardiovascular events. EPO had no effect on norepinephrine-induced vasoconstriction or sodium nitroprusside–induced relaxation. ABT-627, an endothelin type A receptor antagonist, and tempol, a superoxide dismutase mimetic, partially reversed the altered endothelial function in the presence of EPO (P<0.01). Increased expression of endothelin-1 was found in the vessel wall after incubation with EPO.

Conclusions—EPO alters endothelial function of resistance arteries in CKD patients via a mechanism involving in part oxidative stress and signaling through an endothelin type A receptor. EPO-induced endothelial dysfunction could contribute to deleterious effects of EPO described in large interventional trials. (J Am Heart Assoc. 2013;2:e000128 doi: 10.1161/JAHA.113.000128)

Key Words: chronic kidney disease • endothelial function • erythropoietin • resistance artery

Erythropoiesis-stimulating agents were approved 20 years ago for the treatment of anemia associated with chronic kidney disease (CKD) and have been widely accepted for this indication. However, large clinical trials raised concerns about their safety, especially in high-hematocrit target groups. The Normal Hematocrit Study involving patients with congestive heart failure or ischemic heart disease who were receiving hemodialysis was stopped because an interim analysis showed an excess of deaths and nonfatal myocardial infarction in the high-hematocrit group. Clinical trials including patients with stage 3 to 4 CKD also showed an increase in cardiovascular (CV) events and hypertension in the highest-hematocrit group. Whether the increase in CV events was due to hematocrit levels or the dosage of erythropoiesis-stimulating agents required to reach the hematocrit target is still controversial.

Experimental models suggest that EPO influences nitric oxide (NO) production and endothelial function. In human endothelial cell lines, EPO suppresses endothelial NO synthase expression and NO production. In rodent models, EPO has been shown to exert either protective or deleterious effects on endothelial function depending on the rodent model and the size of the studied artery. EPO-induced hypertension in patients and animal models with CKD has
been associated with higher endothelin (ET)-1 plasma levels.\textsuperscript{10} In bovine pulmonary artery endothelial cells, EPO induced ET-1 secretion in a dose-dependent manner.\textsuperscript{11} ET-1 has been shown to induce endothelial dysfunction in, for example, mice overexpressing ET-1\textsuperscript{12} or in the deoxycorticosterone acetate-salt hypertensive rat model.\textsuperscript{13} Taken together, the data obtained in rodents and cell lines suggest that EPO-induced vascular injury could involve ET-1 and endothelial dysfunction. However, in humans, and particularly in CKD patients, the effect of EPO on small resistance arteries has never been studied, and neither has the potential involvement of ET-1.

Resistance artery remodeling and endothelial dysfunction have been associated with various diseases, including hypertension,\textsuperscript{14} obesity,\textsuperscript{15} and diabetes,\textsuperscript{16} and have a negative impact on patient outcomes.\textsuperscript{17,18} Resistance arteries isolated from biopsy samples of gluteal subcutaneous tissue provide a unique opportunity to evaluate the function of human resistance arteries and to test the direct effects of pharmacological agents.\textsuperscript{19} We hypothesized that human recombinant EPO alters endothelial function of subcutaneous resistance arteries isolated from CKD patients through induction of ET-1 expression and oxidative stress. We directly tested the effect of various concentrations of EPO on endothelial function of these vessels and the potential preventive effect of an ET type A receptor (ET\textsubscript{AR}) antagonist and of antioxidant pretreatment.

Subcutaneous Resistance Artery Studies

Gluteal subcutaneous biopsies were performed under local anesthesia (2\% lidocaine). Small arteries (lumen diameter 150 to 300 \(\mu\)m) were isolated and mounted on a pressurized myograph as previously described and validated.\textsuperscript{20,21} Briefly, the vessels were equilibrated for 60 minutes at 60 mm Hg intraluminal pressure in warmed Krebs solution (pH 7.4) containing (in mmol/L): NaCl 120, NaHCO\textsubscript{3} 25, KCl 4.7, KH\textsubscript{2}PO\textsubscript{4} 1.18, MgSO\textsubscript{4} 1.18, CaCl\textsubscript{2} 2.5, EDTA 0.026, and glucose 5.5, bubbled continuously with 95\% air and 5\% CO\textsubscript{2} at 37°C. Small arteries were preincubated for 15 minutes with vehicle (polysorbate-80, 0.3 mg/mL; Sigma Aldrich, concentration recommended by the manufacturer) or EPO (epoietin-\(\alpha\) [Eprex]; Janssen-Cilag) at the indicated concentrations before each curve. Endothelium-dependent relaxation was assessed by measuring the dilatory response to acetylcholine (10\textsuperscript{–9} to 10\textsuperscript{–4} mol/L) in norepinephrine-precontracted vessels (10\textsuperscript{–6} mol/L) in the presence of increasing EPO concentrations (1, 10, and 20 IU/mL). Concentration-response curves to acetylcholine (10\textsuperscript{–9} to 10\textsuperscript{–4} mol/L) in the presence of EPO (20 IU/mL) were repeated after preincubation (15 minutes) with and in the presence of tempol (10\textsuperscript{–3} mol/L; Sigma Aldrich), a superoxide dismutase mimetic, and ABT-627 (10\textsuperscript{–7} mol/L; Abbott Laboratories), a selective ET\textsubscript{AR} antagonist. Endothelium-independent relaxation was assessed with sodium nitroprusside (10\textsuperscript{–8} to 10\textsuperscript{–3} mol/L) in norepinephrine (10\textsuperscript{–6} mol/L)-precontracted vessels in the presence of a non-selective NO synthase inhibitor (10\textsuperscript{–4} mol/L; L-NAME).

Large Artery Evaluation

All patients were studied in a quiet room with controlled temperature of 22°C dedicated to arterial measurements. Brachial blood pressure was measured with use of an automated device (BPM-300; BpTRU Medical Devices) after a 5-minute rest in the sitting position in the absence of observers 6 times at 1-minute intervals, and the mean of the last 5 measurements was used. End-diastolic internal diameter, stroke change in diameter, and intima-media thickness were measured on the right common carotid artery 2 cm before the bifurcation with a high-precision echotracking device (ArtLab System; Esaote), as previously described and validated.\textsuperscript{21} Arterial pressure waveforms were measured at the level of the right radial artery and the common carotid artery with applanation tonometry (SphygmoCor; Atcor Medical), as previously validated.\textsuperscript{22–24} Carotid distensibility was determined from systolic–diastolic variations in arterial cross-sectional area (\(\Delta A\)) and carotid pulse pressure (\(\Delta P\)), assuming the lumen to be circular. The cross-sectional distensibility coefficient (DC) was calculated as \(\Delta A/\Delta P\). Carotid stiffness was calculated as DC\textsuperscript{1/5} as previously described.\textsuperscript{24} Aortic stiffness was measured as the carotid-to-femoral pulse wave velocity according to the foot-to-foot velocity method (SphygmoCor). Pulse transit time (seconds) between the carotid and femoral sites was divided by the distance (m) to obtain carotid-femoral pulse wave velocity (m/s).\textsuperscript{24,25}

Methods

Patients

The study protocol was approved by the Human Research Ethics Review Committee of the Jewish General Hospital, where the study was carried out. All the patients included in the study provided written informed consent to participate. From March 2010 to December 2010, 17 patients with stage 4 CKD were included in the study on the basis of an estimated glomerular filtration rate between 15 and 30 mL/min per 1.73 m\textsuperscript{2} (Modification of Diet in Renal Disease equation).\textsuperscript{20} Patients enrolled were 18 years of age or older, had not been on dialysis, and had not received a kidney transplant. None of the patients had previously received an erythropoiesis-stimulating agent. Pregnant women were excluded. Diabetic nephropathy was identified in 6 patients, nephroangiosclerosis in 4 patients, immunoglobulin A nephropathy in 4 patients, tubulointerstitial nephropathy in 1 patient, and undetermined nephropathy in 2 patients.
and absence of EPO (20 IU/mL). Concentration-response curves to norepinephrine (10⁻³ to 10⁻⁴ mol/L) were performed in the presence and absence of EPO (20 IU/mL).

**Immunohistochemistry Staining**

ET-1 expression in subcutaneous resistance arteries was evaluated by immunohistochemistry. Arteries were fixed in 4% paraformaldehyde for 20 minutes on the myograph at a constant pressure of 60 mm Hg. The artery was transferred to a tube containing the fixative solution, and the fixation was continued for 48 hours with gentle agitation at 4°C. Five-micrometer paraffin-embedded sections were deparaffinized, rehydrated, and washed with Tris-buffered saline (TBS). Thereafter, sections were incubated with a blocking solution (10% normal goat serum [NGS] solution made up in TBS supplemented with 0.1% Tween-20) for 30 minutes, followed by incubations for 15 minutes each with streptavidin and biotin solutions (Vector Laboratories). Sections were incubated with mouse monoclonal anti-ET-1 antibody (1:50; Sigma Aldrich) in blocking solution overnight at 4°C. Sections were washed with TBT and incubated for 30 minutes with 0.3% H₂O₂ to quench endogenous peroxidase and washed with water, TBS, and TBT. Sections were then incubated for 1 hour with blocking solution at room temperature (RT) followed by a biotinylated horse antimouse antibody (1:250; Vector Laboratories) for 1 hour at RT. Sections were washed with TBT and incubated for 1 hour with blocking solution at RT and then incubated with streptavidin-HRP reagent (1:2000; PerkinElmer) in blocking solution for 30 minutes and washed with TBT. The sections were incubated with a solution containing 0.05% 3,3′-diaminobenzidine tetrahydrochloride (Sigma Aldrich) and 0.03% H₂O₂ in TBS for 4 minutes to reveal the conjugate complexes and washed with water to stop the reaction. Finally, the sections were counterstained with methyl green for 1 minute, dehydrated, and mounted with Eukitt mounting reagent (Calibrated Instruments, Inc). Images were captured with Norton Eclipse software.

**Immunofluorescence Staining**

Five-micrometer paraffin-embedded sections were deparaffinized with xylene, rehydrated using solutions of decreasing concentrations of ethanol (100% to 50%), and transferred to phosphate-buffered saline (PBS). Thereafter, sections were incubated with a blocking solution (10% NGS solution made up in PBST [PBS 1× supplemented with 0.1% Tween-20]) for 1 hour at RT. Sections were incubated with a rabbit antihuman ETAR antibody (1:500; Abcam Inc) in blocking solution overnight at 4°C. The sections were washed 3 times with PBST. Sections were incubated with Alexa Fluor 647 goat antirabbit antibody (1:200; Invitrogen Corp) in blocking solution for 1 hour at RT and then washed 3 times with PBST. Sections were stained with 3 μmol/L 4′,6-diamidino-2-phenylindole (DAPI, Invitrogen) in PBS, washed 3 times with PBS, and mounted in Fluoromount (Sigma-Aldrich Canada). Images were captured using a fluorescent microscope Leica DM2000 (Leica Microsystems) and analyzed with use of ImageJ.

**Biological Parameters**

Blood and urine were sampled the day of patient inclusion in the morning under fasting conditions. Blood was collected in EDTA and heparin tubes. Hemoglobin, plasma creatinine, triglycerides, high- and low-density lipoprotein cholesterol, and urinary albumin and creatinine were measured in the Department of Diagnostic Medicine at the Jewish General Hospital according to routine methods. The estimated glomerular filtration rate was determined by the Modification of Diet in Renal Disease formula.20

**Statistical Analyses**

Data are expressed as mean±SD in Table 1. Comparisons between concentration-response curves were performed by 2-way ANOVA considering factor group (fixed) and patient (random) using area under the curve followed by a Newman–Keuls post hoc test. Univariate correlation analyses were used to determine which arterial parameter was associated with the alteration of endothelial function with EPO. A nonparametric test (Mann–Whitney U test) was performed when the variability was different between groups. All tests were performed using NCSS 2007 software (Gerry Hintze, Kaysville, UT). P<0.05 was considered statistically significant.

**Results**

**Studied Population**

Clinical, biological, and arterial characteristics are depicted in Table 1. Seventeen patients with stage 4 CKD (estimated glomerular filtration rate 21.9±7.4 mL/min per 1.73 m²) with controlled hypertension who were aged 63.5±13 years and had not been treated with EPO were included in the study. Approximately half the patients were diabetic and overweight, and 82% exhibited dyslipidemia. Patients were treated mainly with renin–angiotensin system blockers, calcium channel blockers, and statins. Compared with previous published data23,24 on CKD stage 3 and 4, the population studied had comparable values of carotid intima-media thickness.
Vasoactive Effects of EPO on Subcutaneous Small Arteries

To determine whether EPO alters endothelial function through a direct action on the vasculature independent of hemodynamic effects, subcutaneous resistance arteries were isolated from CKD patients and endothelium-dependent relaxation responses to acetylcholine were determined without and with EPO. In the absence of EPO, the maximal relaxation response to acetylcholine was 79% (Figure 1). We tested the roles of nitric oxide, prostaglandins, and ET-1 acetylcholine-induced endothelium-dependent relaxation using the nitric oxide synthase inhibitor L-NAME, the cyclooxygenase inhibitor meclofenamate, and the ETAR antagonist ABT-627. The maximal relaxation response to acetylcholine was reduced by 54% in the presence of L-NAME but was not altered significantly by meclofenamate or the selective ET AR antagonist ABT-627 (Figure 1).}

Table 1. Clinical, Biological, and Arterial Characteristics of the 17 Patients Included

| Parameters                              | Mean (SD) |
|-----------------------------------------|-----------|
| **Demographic parameters**             |           |
| Age, y                                  | 63.5 (12.6) |
| Sex, % male                            | 53        |
| Hypertension, %                        | 100       |
| Dyslipidemia, %                        | 82        |
| Diabetes, %                            | 47        |
| Cardiovascular history, %              | 23        |
| Calcium channel blockers, %            | 68        |
| ACE inhibitors, %                      | 19        |
| ARBs, %                                | 62        |
| Diuretics, %                           | 50        |
| β-Blockers, %                          | 31        |
| Statins, %                             | 75        |
| EPO, %                                 | 0         |
| **Clinical parameters**                |           |
| Systolic blood pressure, mm Hg         | 130 (17)  |
| Diastolic blood pressure, mm Hg        | 72 (10)   |
| Mean blood pressure, mm Hg             | 91 (11)   |
| Heart rate, bpm                        | 69 (8)    |
| BMI, kg/m²                              | 27.2 (6.3) |
| **Biological parameters**              |           |
| Creatinine, μmol/L                     | 301 (82)  |
| eGFR, mL/min                           | 21.9 (7.4) |
| UACR, g/g creatinine                   | 0.33 (0.16) |
| Hemoglobin, g/dL                       | 109 (13.1) |
| Total cholesterol, mmol/L              | 4.1 (1.7)  |
| HDL cholesterol, mmol/L                | 1.2 (0.7)  |
| LDL cholesterol, mmol/L                | 1.9 (1.1)  |
| Triglycerides, mmol/L                  | 2 (1.2)    |
| **Large artery function**              |           |
| Carotid-femoral pulse wave velocity, m/s | 13.0 (3.4) |
| Carotid intima-media thickness, μm     | 607 (143)  |
| Carotid stiffness, m/s                 | 7.3 (1.7)  |

Values are mean±SD or % of subjects (N=17). ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocker; EPO, recombinant human erythropoietin; BMI, body mass index; eGFR, estimated glomerular filtration rate; UACR, urinary albumin/creatinine ratio; HDL, high-density lipoprotein; LDL, low-density lipoprotein.

Vasoactive Effects of EPO on Subcutaneous Small Arteries

To determine whether EPO alters endothelial function through a direct action on the vasculature independent of hemodynamic effects, subcutaneous resistance arteries were isolated from CKD patients and endothelium-dependent relaxation responses to acetylcholine were determined without and with EPO. In the absence of EPO, the maximal relaxation to acetylcholine was 79% (Figure 1). We tested the roles of nitric oxide, prostaglandins, and ET-1 acetylcholine-induced endothelium-dependent relaxation using the nitric oxide synthase inhibitor L-NAME, the cyclooxygenase inhibitor meclofenamate, and the ETAR antagonist ABT-627. The maximal relaxation response to acetylcholine was reduced by 54% in the presence of L-NAME but was not altered significantly by meclofenamate or the selective ET AR antagonist ABT-627 (Figure 1).

To determine the effect of EPO, subcutaneous resistance arteries were incubated 15 minutes with EPO and the endothelium-dependent relaxation response to acetylcholine was determined in presence of EPO. EPO impaired endothelium-dependent relaxation response to acetylcholine in a concentration-dependent manner (slope −3.8 AUC unit/EPO unit, P=10⁻⁶). The maximal response to acetylcholine with EPO at 1, 10, and 20 IU/mL was reduced by 12%, 34%, and
Erythropoietin and Vascular Reactivity

Mechanisms of EPO-Induced Small Artery Vasoactive Effects

We tested the ability of the selective ET<sub>A</sub>R antagonist ABT-627 to prevent the vascular effects of EPO. ABT-627 reduced the impairment of endothelial function induced by EPO. The maximal relaxation response to acetylcholine with EPO 20 IU/mL was reduced by 44% compared with the group without inhibitor, and in the presence of ABT-627, the response was reduced by only 14% (2-way ANOVA, group effect P<10<sup>−6</sup>) (Figure 4A). ABT-627 did not affect endothelium-dependent relaxation in the absence of EPO.

Incubation of small arteries with EPO at 20 IU/mL during 1 hour significantly increased the expression of ET-1 in the
vascular wall (Figure 5). Altogether, these results suggest that the vascular effects of EPO are mediated by ET-1. In addition, ETAR was 2-fold higher in patients with a history of CV events than in patients without a history of CV events (Figure 6).

We tested the effect of tempol, an antioxidant superoxide dismutase mimetic, on endothelial dysfunction induced by EPO. The maximal relaxation response to acetylcholine with EPO 20 IU/mL was reduced by 45% compared with the group without inhibitor, whereas in the presence of tempol, the response was reduced by only 12% (2-way ANOVA, group effect $P<10^{-5}$) (Figure 4B). Tempol did not affect the endothelium-dependent relaxation to acetylcholine in the absence of EPO.

**Discussion**

In the present study, we demonstrate for the first time that EPO alters endothelial function of small arteries isolated from human subjects with stage 4 CKD, and particularly in patients with a history of CV events. In addition, we provide insight into potential mechanisms by showing that the impairment of endothelial function could be partially prevented by a specific antagonist of ETAR and by a superoxide dismutase mimetic. Finally, we show that EPO induced an increase in ET-1 expression in the wall of resistance arteries.

**Interpretation of the Data**

The hypothesis that EPO has a direct effect on vascular function is supported by the observation that the EPO receptor is widely expressed in various tissues, including endothelial cells. The endothelial cell EPO receptor has an intermediate affinity for EPO ($\approx 1$ nmol/L), between the affinity of the receptor on erythrocyte precursors...
EPO administration in CKD patients and in rats induces an increase in blood pressure that could be related to direct effects of EPO on vascular function or that could be secondary to an increase in hematocrit. In vivo, in humans, it is almost impossible to disentangle the direct effect of EPO on the vessel wall from the deleterious effects of increases in hematocrit. Here, we demonstrate ex vivo in human small arteries from CKD patients a direct effect of EPO on endothelial function, which could participate in the increased blood pressure observed in CKD patients treated with EPO. The results of the present study may explain those of large clinical studies showing that for similar hematocrit levels, patients treated with EPO experience more CV events. For example, in the Reduction of Infarct Expansion and Ventricular Remodeling With Erythropoietin After Large Myocardial Infarction (REVEAL) study involving patients with acute myocardial infarction, a single injection of epoietin alfa (60 000 IU) was associated with poor CV outcomes without differences in hematocrit levels between the control and the treated group.

Several mechanisms could participate in the impairment of endothelial function induced by EPO. EPO increases oxidative stress in the arterial wall. In human coronary artery endothelial cells, EPO at 5 and 20 IU/mL decreased NO production in response to acetylcholine stimulation, with a parallel reduction in endothelial NO synthase protein abundance. In agreement, we found that tempol, a superoxide dismutase mimetic, partially prevented endothelial dysfunction induced by EPO. Another potential mechanism is ET-1 production. Incubation of human umbilical vein endothelial cells with EPO increased ET-1 generation in a concentration-dependent manner. In end-stage renal disease patients, a significant increase in plasma ET-1 levels was observed after a single dose of EPO. The potential role of ET-1 in EPO-induced hypertension is underlined by the fact that ET receptor blockade prevented hypertension induced by EPO administration to uremic rats. In the present study, incubation of small arteries with EPO induced an increase in ET-1 expression in the vascular wall. In addition, endothelial dysfunction observed in the presence of EPO was partially prevented by ABT-627, an ET antagonist.

Cardiovascular and renal risk factors may influence the alteration of endothelial function found with EPO. A history of CV disease was associated with a greater effect of EPO on the endothelium. Carotid stiffness, which is a marker of CV risk in CKD patients, was also associated with the alteration in endothelial function with EPO. In addition, our study provides support for the notion that ET-1 is involved in the vascular effects of EPO. An increased level of ET receptor was observed in patients with a history of CV events, which may make them more sensitive to an increase in ET-1 expression. These observations are in agreement with experimental studies showing a major alteration of endothelial function in mice overexpressing ET-1 treated with EPO compared with wild-type controls. In another rodent model, the increase in blood pressure in response to EPO was observed only in uremic rats and not in the control group despite a similar increase in hematocrit. The fact that the expression of the EPO receptor increases in endothelial cells in pathological conditions such as hypoxia could in part explain these observations.

Methodological Issues
The strength of this study is that the effect of EPO was studied directly on small resistance arteries from humans with CKD. The tissues used for this study were not surgical samples isolated during a scheduled surgery, which could induce selection bias, but were obtained specifically for this study from gluteal subcutaneous biopsies after informed consent. In addition, this study provides for the first time a possible explanation for the increase in blood pressure and CV events observed in patients with CKD or with coronary heart disease who are treated with EPO. The choice of the population studied was driven by the fact that patients with stage 4 CKD are more likely to receive EPO as part of standard care. In the present study, we believe that the choice of an ex vivo study is an advantage because the effect of EPO on subcutaneous resistance arteries could be dissociated from effects on hematocrit and hemodynamics. Since the goal of this study was to evaluate EPO effects in vivo in the context of CKD, no healthy controls were investigated for comparison, which is a limitation of the study. The concentrations of EPO used in this study were chosen based on published experimental data and could be considered as relatively high concentrations. However, the maximal concentration measured after 1 intravenous injection of epoietin-α 150 IU/kg in hemodialysis patients was 2.4 IU/mL. In addition, EPO was administered into the chamber, outside the artery, and had to diffuse through the vascular wall. As a consequence, the concentration of EPO that reached the media and the endothelium is likely much lower.

Perspectives
In the present study, we provide for the first time important insights into mechanisms regarding the effects of EPO on
vascular function in humans with stage 4 CKD. These actions are mediated via ET-1 secretion and oxidative stress. The impairment of endothelial function induced by EPO could contribute to increases in blood pressure and CV events observed in large interventional trials.

Acknowledgments

We thank Kathy Delouya, RN, Tracy Hodge, RN, and Chantal Paquette, RN, for their excellent nursing help. Aspects of this article were presented in abstract form at the European Society of Hypertension meeting in Milan, Italy, June 2011, and at the meeting of the Council for High Blood Pressure Research in Orlando, FL, USA, September 2011.

Sources of Funding

This study was supported by grants 37917 and 82790 from the Canadian Institutes of Health Research (CIHR), by a Canada Research Chair (CRC) on Hypertension and Vascular Research from CIHR/Government of Canada CRC Program, and by the Canada Fund for Innovation, all to E. L. Schiffrin. M. Briet was supported by a fellowship from Heart and Stroke Foundation Canada.

Disclosures

None.

References

1. Unger EF, Thompson AM, Blank MJ, Temple R. Erythropoiesis-stimulating agents—time for a reevaluation. N Engl J Med. 2010;362:189–192.
2. Besarab A, Bolton WK, Browne JK, Egie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339:584–590.
3. Singh AK, Szczezec L, Tang KL, Barnhart H, Platto C, Mazza M, Brignani A, Rosei CA, Ricotta D, Caimi L, Rosei EA. Structural alterations in subcutaneous small resistance arteries predict changes in the renal function of hypertensive patients. J Hypertens. 2010;28:1951–1958.
4. Rizzoni D, Porteri E, Boari GE, De Cucci C, Steiman I, Muiesan ML, Castellano M, Miclini A, Agabiti-Rosei E. Prognostic significance of small-artery structure in hypertension. Circulation. 2003;108:2230–2235.
5. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger M, Uscio LV, Smith LA, Santhanam AV, Richardson D, Nath KA, Katusic ZS. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2009;361:2019–2032.
6. Wang XQ, Vaziri ND. Erythropoietin depresses nitric oxide synthase expression by human endothelial cells. J Hypertens. 1999;17:1142–1148.
7. Toba H, Morishita M, Tojo C, Nakano A, Oshima Y, Kojima Y, Yoshida M, Nakashima K, Wang J, Kobara M, Nakata T. Recombinant human erythropoietin ameliorated endothelial dysfunction and macrophage infiltration by increasing nitric oxide in hypertension 5/6 nephrectomized rat aorta. Eur J Pharmacol. 2011;656:81–87.
8. Barhoumi T, Jallat I, Berthelot A, Laurent P. Human recombinant erythropoietin alters the flux-dependent vasodilation of in vitro perfused rat mesenteric arteries with unbalanced endothelial endothelin-1/nitric oxide ratio. Can J Physiol Pharmacol. 2011;89:435–443.
9. Larivière R, Lebel M. Endothelin-1 in chronic renal failure and hypertension. Can J Physiol Pharmacol. 2003;8:561–567.
10. Carlini RG, Dusso AS, Obialo CI, Alvarez UM, Rothstein M. Recombinant human erythropoietin (rHuEPO) increases endothelin-1 release by endothelial cells. Kidney Int. 1993;43:1010–1014.
11. Amiri F, Virdis A, Neves MF, Igizar M, Seidah NG, Touyz RM, Reidelhuber TL, Schiffrin EL. Endothelin-restricted overexpression of human endothelin-1 causes vascular remodeling and endothelial dysfunction. Circulation. 2004;110:2233–2240.
12. Callera GE, Touyz RM, Teixeira SA, Muscaria MN, Canvalho MH, Fortes ZB, Nigro D, Schiffrin EL, Tostes RC. ETA receptor blockade decreases vascular superoxide generation in DOCA-salt hypertension. Hypertension. 2003;42:811–817.
13. Intengan HD, Deng LY, Li JS, Schiffrin EL. Mechanics and composition of human subcutaneous resistance arteries in essential hypertension. Hypertension. 1999;33:569–574.
14. Greenstein AS, Khavandi K, Withers SB, Sonoyama K, Clancy O, Jeziorska M, Laing I, Yates AP, Pemberton PW, Malik RA, Heagerty AM. Local inflammation and hypoxia abolish the protective anticontractile properties of perivascular fat in obese patients. Circulation. 2009;119:1661–1670.
15. Rizzoni D, Rosei EA. Small artery remodeling in diabetes mellitus. Nutr Metab Cardiovasc Dis. 2009;19:587–592.
16. Boari GE, Rizzoni D, De Cucci C, Porteri E, Avanzi D, Platto C, Mazza M, Brignani A, Rosei CA, Ricotta D, Caimi L, Rosei EA. Structural alterations in subcutaneous small resistance arteries predict changes in the renal function of hypertensive patients. J Hypertens. 2010;28:1951–1958.
17. Rizzoni D, Porteri E, Boari GE, De Cucci C, Steiman I, Muiesan ML, Castellano M, Miclini A, Agabiti-Rosei E. Prognostic significance of small-artery structure in hypertension. Circulation. 2003;108:2230–2235.
18. Savoia C, Touyz RM, Volpe M, Schiffrin EL. Angiotensin type 2 receptor in resistance arteries of type 2 diabetic hypertensive patients. Hypertension. 2007;49:341–346.
19. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann Intern Med. 1999;130:461–470.
20. Paini A, Bontouryie P, Calvet D, Zidi M, Agabiti-Rosei E, Laurent S. Multiaxial mechanical characteristics of carotid plaque: analysis by multiaarray echo-tracking system. Stroke. 2007;38:117–123.
21. Chen CH, Nevo E, Fetics B, Pak PH, Yin FC, Maughan WL, Kass DA. Estimation of central aortic pulse waveform by mathematical transformation of radial tonometry pressure. Validation of generalized transfer function. Circulation. 1997;95:1827–1836.
22. Briet M, Bozec E, Laurent S, Fassot C, London GM, Jacquot C, Froissart M, Houiller P, Bontouryie P. Arterial stiffness and enlargement in mild-to-moderate chronic kidney disease. Kidney Int. 2006;69:350–357.
23. Briet M, Collin C, Karras A, Laurent S, Bozec E, Jacquot C, Stengel B, Houiller P, Froissart M, Bontouryie P. Arterial remodeling associates with CKD progression. J Am Soc Nephrol. 2011;22:967–974.
24. Asmar R, Benetos A, Topouchian J, Laurent P, Pannier B, Brisac AM, Target R, Levy BI. Assessment of arterial distensibility by automatic pulse wave velocity measurement. Validation and clinical application studies. Hypertension. 1995;26:485–490.
25. Schiffrin EL, Deng LY, Larochelle P. Effects of a beta-blocker or a converting enzyme inhibitor on resistance arteries in essential hypertension. Hypertension. 1994;23:83–91.
26. Savoia C, Touyz RM, Amiri F, Schiffrin EL. Selective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patients. Hypertension. 2008;51:432–439.
27. Beleslin-Cekic BB, Cokic VP, Yu X, Weksler BB, Schechter AN, Naguchi CT. Erythropoietin and hypoxia stimulate erythropoietin receptor and nitric oxide production by endothelial cells. Blood. 2004;104:2073–2080.
28. Brochu E, Lacasse S, Lariviire R, Kingma I, Grohe JH, Lebel M. Differential effects of endothelin-1 antagonists on erythropoietin-induced hypertension in renal failure. J Am Soc Nephrol. 1999;10:1440–1446.
29. Najjar SS, Rao SV, Meloni C, Raman SV, Povsic TJ, Melton L, Barsness GW, Prather K, Heitner JF, Kilaru R, Gruberg L, Hasselblad V, Greenbaum AB, Patel M, Kim RJ, Talan M, Ferrucci L, Longo DL, Lakatta EG, Harrington RA. Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial. JAMA. 2011;305:1863–1872.
30. Rancourt ME, Rodrigue ME, Agharazii M, Lariviire R, Lebel M. Role of oxidative stress in erythropoietin-induced hypertension in uremic rats. Am J Hypertens. 2010;23:314–320.
32. Bode-Boger SM, Boger RH, Kuhn M, Radermacher J, Frolich JC. Recombinant human erythropoietin enhances vasoconstrictor tone via endothelin-1 and constrictor prostanoids. *Kidney Int*. 1996;50:1255–1261.

33. Miyashita K, Tojo A, Kimura K, Goto A, Omata M, Nishiyama K, Fujita T. Blood pressure response to erythropoietin injection in hemodialysis and predialysis patients. *Hypertens Res*. 2004;27:79–84.

34. Blacher J, Pannier B, Guerin AP, Marchais SJ, Safar ME, London GM. Carotid arterial stiffness as a predictor of cardiovascular and all-cause mortality in end-stage renal disease. *Hypertension*. 1998;32:570–574.

35. Barhoumi T, Briet M, Paradis P, Schiffrin EL. An endothelin receptor type A antagonist prevents the deleterious vascular effects of erythropoietin in mice overexpressing human preproendothelin-1. *Hypertension*. 2011;58: e44.

36. Lacasse MS, Kingma I, Lariviére R, Grose JH, Lebel M. Uremia enhances the blood pressure response to erythropoietin. *Clin Exp Hypertens*. 1997;19:389–401.

37. Nielsen OJ. Pharmacokinetics of recombinant human erythropoietin in chronic haemodialysis patients. *PharmacoI Toxicol*. 1990;66:83–86.